US Health Institute’s Genetic Research Launches New Patient Portal
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
A new portal created for patients to enter health history has been designed to provide a new opportunity for investigators to obtain a better determination of the human genome.
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
As tumors grow, cancer cells constantly make errors during DNA copying and division. Many of these errors involve the gain or loss of entire chromosomes, resulting in a diverse range of chromosome configurations... Read more
World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
Lung cancer remains the deadliest cancer in China, largely because many patients are diagnosed at an advanced stage when treatment options are limited. Early symptoms are often mild or absent, and while... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







